Allogene Therapeutics
Jeff McLeroy, MD, currently serves as the Vice President of Drug Safety & Pharmacovigilance at Allogene Therapeutics, a position held since November 2024. Prior to this role, Jeff held various positions in clinical development and drug safety at Synthekine, Instil Bio, and Kite Pharma. Jeff's experience includes significant leadership roles in patient safety at Kite Pharma and safety science at Genentech. In the earlier stages of their career, Jeff was a Medical Oncologist/Hematologist at Kaiser Permanente, where specialization areas included lung cancer, head/neck cancer, and survivorship/preventive oncology. Additionally, Jeff contributed to academia as an Assistant Clinical Professor at UC Davis School of Medicine and served as Chief of Medical Oncology/Hematology at the VA Martinez Medical Center, where program expansion and patient care enhancement were major achievements. Educational credentials include a Doctor of Medicine degree from UC Davis School of Medicine and fellowship training in Hematology and Medical Oncology.
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.